National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer

Christina A. Minami, Karl Y. Bilimoria, Nora M. Hansen, Jonathan B. Strauss, John P. Hayes, Joe M. Feinglass, Kevin P. Bethke, Nicholas R. Rydzewski, David P. Winchester, Brian E. Palis, Anthony D. Yang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Current guidelines recommend postmastectomy radiotherapy (PMRT) for patients with ≥4 positive lymph nodes and suggest strong consideration of PMRT in those with 1–3 positive nodes. These recommendations were incorporated into a Commission on Cancer quality measure in 2014. However, national adherence with these recommendations is unknown. Our objectives were to describe PMRT use in the United States in patients with stage I to III invasive breast cancer and to examine possible factors associated with the omission of PMRT. Methods: From the National Cancer Data Base, 753,536 mastectomies at 1123 hospitals were identified from 1998 to 2011. PMRT use over time was examined using random effects logistic regression analyses, adjusting for patient, tumor, and hospital characteristics. Analyses were stratified by nodal status (≥4 nodes positive, 1–3 nodes positive, node negative). Results: The proportion of patients receiving PMRT increased from 1998 to 2011 (>4 positive nodes: 56.2 to 66.6 %; 1–3 positive nodes: 28.0 to 39.1 %; node-negative: 8.3 to 10.0 %, p < 0.001 for all). In adjusted analyses, patients with ≥4 positive nodes were more likely to have PMRT omitted if they had smaller tumors. Patients with 1–3 positive nodes were more likely to have PMRT omitted if they had lower grade or smaller tumors. Irrespective of patients’ nodal status, PMRT utilization rates decreased as age increased. Conclusions: Though PMRT rates increased over time in patients with ≥4 and 1–3 positive nodes, PMRT in patients with ≥4 positive nodes remains underutilized. Feedback to hospitals using the new Commission on Cancer PMRT measure may help to improve adherence rates.

Original languageEnglish (US)
Pages (from-to)2446-2455
Number of pages10
JournalAnnals of Surgical Oncology
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Radiotherapy
Radiation
Breast Neoplasms
Neoplasms
Therapeutics
Mastectomy
Logistic Models
Lymph Nodes
Regression Analysis
Databases
Guidelines

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Minami, C. A., Bilimoria, K. Y., Hansen, N. M., Strauss, J. B., Hayes, J. P., Feinglass, J. M., ... Yang, A. D. (2016). National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer. Annals of Surgical Oncology, 23(8), 2446-2455. https://doi.org/10.1245/s10434-016-5257-5

National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer. / Minami, Christina A.; Bilimoria, Karl Y.; Hansen, Nora M.; Strauss, Jonathan B.; Hayes, John P.; Feinglass, Joe M.; Bethke, Kevin P.; Rydzewski, Nicholas R.; Winchester, David P.; Palis, Brian E.; Yang, Anthony D.

In: Annals of Surgical Oncology, Vol. 23, No. 8, 01.08.2016, p. 2446-2455.

Research output: Contribution to journalArticle

Minami, CA, Bilimoria, KY, Hansen, NM, Strauss, JB, Hayes, JP, Feinglass, JM, Bethke, KP, Rydzewski, NR, Winchester, DP, Palis, BE & Yang, AD 2016, 'National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer', Annals of Surgical Oncology, vol. 23, no. 8, pp. 2446-2455. https://doi.org/10.1245/s10434-016-5257-5
Minami, Christina A. ; Bilimoria, Karl Y. ; Hansen, Nora M. ; Strauss, Jonathan B. ; Hayes, John P. ; Feinglass, Joe M. ; Bethke, Kevin P. ; Rydzewski, Nicholas R. ; Winchester, David P. ; Palis, Brian E. ; Yang, Anthony D. / National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer. In: Annals of Surgical Oncology. 2016 ; Vol. 23, No. 8. pp. 2446-2455.
@article{507e9a7c1eae417c8867889c74df4358,
title = "National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer",
abstract = "Background: Current guidelines recommend postmastectomy radiotherapy (PMRT) for patients with ≥4 positive lymph nodes and suggest strong consideration of PMRT in those with 1–3 positive nodes. These recommendations were incorporated into a Commission on Cancer quality measure in 2014. However, national adherence with these recommendations is unknown. Our objectives were to describe PMRT use in the United States in patients with stage I to III invasive breast cancer and to examine possible factors associated with the omission of PMRT. Methods: From the National Cancer Data Base, 753,536 mastectomies at 1123 hospitals were identified from 1998 to 2011. PMRT use over time was examined using random effects logistic regression analyses, adjusting for patient, tumor, and hospital characteristics. Analyses were stratified by nodal status (≥4 nodes positive, 1–3 nodes positive, node negative). Results: The proportion of patients receiving PMRT increased from 1998 to 2011 (>4 positive nodes: 56.2 to 66.6 {\%}; 1–3 positive nodes: 28.0 to 39.1 {\%}; node-negative: 8.3 to 10.0 {\%}, p < 0.001 for all). In adjusted analyses, patients with ≥4 positive nodes were more likely to have PMRT omitted if they had smaller tumors. Patients with 1–3 positive nodes were more likely to have PMRT omitted if they had lower grade or smaller tumors. Irrespective of patients’ nodal status, PMRT utilization rates decreased as age increased. Conclusions: Though PMRT rates increased over time in patients with ≥4 and 1–3 positive nodes, PMRT in patients with ≥4 positive nodes remains underutilized. Feedback to hospitals using the new Commission on Cancer PMRT measure may help to improve adherence rates.",
author = "Minami, {Christina A.} and Bilimoria, {Karl Y.} and Hansen, {Nora M.} and Strauss, {Jonathan B.} and Hayes, {John P.} and Feinglass, {Joe M.} and Bethke, {Kevin P.} and Rydzewski, {Nicholas R.} and Winchester, {David P.} and Palis, {Brian E.} and Yang, {Anthony D.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1245/s10434-016-5257-5",
language = "English (US)",
volume = "23",
pages = "2446--2455",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - National Evaluation of the New Commission on Cancer Quality Measure for Postmastectomy Radiation Treatment for Breast Cancer

AU - Minami, Christina A.

AU - Bilimoria, Karl Y.

AU - Hansen, Nora M.

AU - Strauss, Jonathan B.

AU - Hayes, John P.

AU - Feinglass, Joe M.

AU - Bethke, Kevin P.

AU - Rydzewski, Nicholas R.

AU - Winchester, David P.

AU - Palis, Brian E.

AU - Yang, Anthony D.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: Current guidelines recommend postmastectomy radiotherapy (PMRT) for patients with ≥4 positive lymph nodes and suggest strong consideration of PMRT in those with 1–3 positive nodes. These recommendations were incorporated into a Commission on Cancer quality measure in 2014. However, national adherence with these recommendations is unknown. Our objectives were to describe PMRT use in the United States in patients with stage I to III invasive breast cancer and to examine possible factors associated with the omission of PMRT. Methods: From the National Cancer Data Base, 753,536 mastectomies at 1123 hospitals were identified from 1998 to 2011. PMRT use over time was examined using random effects logistic regression analyses, adjusting for patient, tumor, and hospital characteristics. Analyses were stratified by nodal status (≥4 nodes positive, 1–3 nodes positive, node negative). Results: The proportion of patients receiving PMRT increased from 1998 to 2011 (>4 positive nodes: 56.2 to 66.6 %; 1–3 positive nodes: 28.0 to 39.1 %; node-negative: 8.3 to 10.0 %, p < 0.001 for all). In adjusted analyses, patients with ≥4 positive nodes were more likely to have PMRT omitted if they had smaller tumors. Patients with 1–3 positive nodes were more likely to have PMRT omitted if they had lower grade or smaller tumors. Irrespective of patients’ nodal status, PMRT utilization rates decreased as age increased. Conclusions: Though PMRT rates increased over time in patients with ≥4 and 1–3 positive nodes, PMRT in patients with ≥4 positive nodes remains underutilized. Feedback to hospitals using the new Commission on Cancer PMRT measure may help to improve adherence rates.

AB - Background: Current guidelines recommend postmastectomy radiotherapy (PMRT) for patients with ≥4 positive lymph nodes and suggest strong consideration of PMRT in those with 1–3 positive nodes. These recommendations were incorporated into a Commission on Cancer quality measure in 2014. However, national adherence with these recommendations is unknown. Our objectives were to describe PMRT use in the United States in patients with stage I to III invasive breast cancer and to examine possible factors associated with the omission of PMRT. Methods: From the National Cancer Data Base, 753,536 mastectomies at 1123 hospitals were identified from 1998 to 2011. PMRT use over time was examined using random effects logistic regression analyses, adjusting for patient, tumor, and hospital characteristics. Analyses were stratified by nodal status (≥4 nodes positive, 1–3 nodes positive, node negative). Results: The proportion of patients receiving PMRT increased from 1998 to 2011 (>4 positive nodes: 56.2 to 66.6 %; 1–3 positive nodes: 28.0 to 39.1 %; node-negative: 8.3 to 10.0 %, p < 0.001 for all). In adjusted analyses, patients with ≥4 positive nodes were more likely to have PMRT omitted if they had smaller tumors. Patients with 1–3 positive nodes were more likely to have PMRT omitted if they had lower grade or smaller tumors. Irrespective of patients’ nodal status, PMRT utilization rates decreased as age increased. Conclusions: Though PMRT rates increased over time in patients with ≥4 and 1–3 positive nodes, PMRT in patients with ≥4 positive nodes remains underutilized. Feedback to hospitals using the new Commission on Cancer PMRT measure may help to improve adherence rates.

UR - http://www.scopus.com/inward/record.url?scp=84966700333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966700333&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5257-5

DO - 10.1245/s10434-016-5257-5

M3 - Article

AN - SCOPUS:84966700333

VL - 23

SP - 2446

EP - 2455

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -